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doi:10.1016/j.jtcvs.2006.07.036bjectives: The altered expression of matrix metalloproteinases and their inhibitors
nfluences the formation of atherosclerotic abdominal aortic aneurysms. Their associa-
ion with thoracic aneurysms is less clear. This study describes the expression of
etalloproteinases and their inhibitors in atherosclerotic and nonatherosclerotic thoracic
neurysms, and compares these with age-matched controls.
ethods: Matrix metalloproteinase-2 and 9 activity were measured by antibody
apture, and tissue inhibitor-1 and 2 levels were measured by enzyme-linked
mmunosorbent assay in 24 patients with atherosclerotic aneurysms and in 63
atients with nonatherosclerotic aneurysms. Gene expression was assessed with
everse transcriptase polymerase chain reaction. The results were compared with 17
ontrols.
esults: Data are in nanograms per milligram of protein. Matrix metalloproteinase-2
ctivity was greater in controls than in the atherosclerotic and nonatherosclerotic
roups (80  67 vs 49  50 and 35  44, P  .002). Matrix metalloproteinase-9
ctivity was greater in the atherosclerotic group than in the nonatherosclerotic group
nd controls (11.7  15.7 vs 2.5  2.2 and 1.7  1.9, P  .001). Tissue inhibitor-1
nd 2 levels were greater in controls than in either aneurysm group (tissue inhibitor
f metalloproteinase-1: 376  192 vs 234  233 and 174  148, P  .003; tissue
nhibitor of metalloproteinase-2: 143  74 vs 14  13 and 27  43, P  .001).
therosclerotic aneurysms expressed more matrix metalloproteinase mRNA than
ontrols.
onclusions: The metalloproteinase/tissue inhibitor phenotype of atherosclerotic
horacic aneurysms is similar to that of abdominal aneurysms. The diminished
xpression of metalloproteinases and tissue inhibitors in nonatherosclerotic thoracic
neurysms relative to aged controls may represent a loss of smooth muscle cells.
horacic aortic aneurysms are characterized by extracellular matrix destruction
involving the fragmentation of elastic lamellae within the media, ineffective
elastogenesis, and disordered collagen deposition. Similar changes are seen in
bdominal aortic aneurysms, where increases in the elastinolytic and collagenolytic
ctivity of matrix metalloproteinases (MMPs) are well documented. 1-3 The MMPs,
long with their inhibitors, the tissue inhibitor of metalloproteinases (TIMP), are
onstitutively expressed and are key components in the pathway toward normal and
athologic extracellular matrix turnover.4 An imbalance in the proteolytic equilib-
ium between MMPs and TIMP may contribute to abdominal aortic aneurysm
ormation.5
Thoracic aortic aneurysms often have histopathologic features that differ from
bdominal aortic aneurysms. Abdominal aortic aneurysms are commonly of ath-
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1
A
CDrosclerotic cause and contain a chronic inflammatory cell
nfiltrate.2,3 Atherosclerotic thoracic aortic aneurysms have
imilar histopathologic characteristics. Many types of tho-
acic aortic aneurysms, however, are not associated with
therosclerosis. They have no associated inflammatory cell
nfiltrate and are characterized by extensive cystic medial
ecrosis, represented by disruption of medial elastin and
ollagen with focal loss of smooth muscle cells.6 Thoracic
neurysms of this type are commonly associated with an-
uloaortic ectasia, bicuspid aortic valves, or heritable con-
ective tissue disorders, such as Marfan syndrome. Therefore,
therosclerotic and nonatherosclerotic thoracic aneurysms de-
elop from different inciting events and may have divergent
xtracellular matrix proteolytic phenotypes.
The purpose of this study was to characterize the pro-
eolytic phenotype of these 2 subtypes of thoracic aneu-
ysms by measuring MMP-2 and MMP-9 enzyme activity,
IMP-1 and TIMP-2 protein levels, and MMP/TIMP gene
xpression, and compare these with nonaneurysmal control
horacic aorta. We hypothesized that atherosclerotic tho-
acic aneurysms are associated with increased expression of
MP-9 when compared with nonatherosclerotic thoracic
neurysms and nonaneurysmal aorta. We further hypothe-
ized that both subtypes of thoracic aneurysms would ex-
ress an enhanced proteolytic phenotype when compared
ith nonaneurysmal aorta.
aterials and Methods
atients
horacic aortic aneurysm tissue was collected at operation from 87
atients undergoing elective repair at a single tertiary care institu-
ion (Fletcher Allen Health Care, Burlington, Vt) between Decem-
er of 2000 and April of 2005. Ascending aortic samples were
aken from the anterior aspect of the aorta in the region of the
reatest dilatation, which was usually within 2 cm of the sinotu-
ular ridge. Samples from the descending thoracic aorta were
aken from the anterior aspect of the aneurysm, also in the region
f the greatest dilatation. Gross and histologic analyses were used
o designate each aneurysm as atherosclerotic (n  24) or nonath-
rosclerotic (n  63) in origin. Atherosclerosis was distinguished
y the presence of chronic inflammatory cells, disruption of the
ntimal layer, and deposition of atheromatous plaque within the
edia. Nonatherosclerotic aneurysms were characterized by the ab-
ence of chronic inflammatory cells, the fragmentation of the elastic
amellae within the media, mucopolysaccharide pooling, and the loss
f smooth muscle cells. Control tissue was obtained from discarded
ortic punch biopsies of the nonaneurysmal ascending aorta of
atients undergoing routine coronary artery bypass grafting (n 
Abbreviations and Acronyms
MMP matrix metalloproteinase
TIMP tissue inhibitor of metalloproteinases7). Control tissue was not used if there was evidence of gross t
56 The Journal of Thoracic and Cardiovascular Surgery ● Janutheromatous disease. Tissue was placed in phosphate-buffered
aline solution at 4°C, transported to the laboratory, snap-frozen in
iquid nitrogen, and stored at 80°C until the time of preparation
nd analysis.
The medical record of each patient was reviewed, and impor-
ant clinical and demographic variables were recorded, including
ge, sex, vascular disease risk factors, antihypertensive drug ther-
py, and presence or absence of a bicuspid valve. Informed con-
ent was obtained, and the study met the guidelines set forth by the
nstitutional review board at this institution.
issue Preparation
issue (0.15-0.40 g wet weight) was homogenized in 1 mL of 50
mol/L Tris-HCL buffer solution (1.5 mmol/L NaCl, 0.5 mmol/L
aCl2, 1 mol/L ZnCl2, and 0.01% [v/v] BRIJ 35, pH 7.4) at 4°C
nd centrifuged at 8000 rpm for 5 minutes, and the supernatant was
ollected. The pellets were resuspended in 1 mL of 50 mmol/L
ris-HCL, homogenized a second time, and centrifuged at 8000 rpm
or 5 minutes. Combined supernatants were spun at 10,000 rpm for 10
inutes, and the final supernatant was collected and used for analysis.
otal protein concentration (milligrams/milliliter) was measured in
ach final supernatant using a protein assay kit (BIO-RAD, Her-
ules, Calif) for standardization.
MP Activity and TIMP Protein Analysis
he endogenous and total activity of MMP-2 and MMP-9 were
uantified in the supernatants by activity assays (MMP-2 and
MP-9 Biotrak Activity Assay System, Amersham Biosciences
orp, Piscataway, NJ). The activity assay is based on an antibody-
apture technique and has been described.7 The term “endogenous
ctivity” refers to extractable bioactive MMP, whereas the term
total activity” refers to the detectable endogenous activity plus the
rtificially activated proenzyme. The levels of TIMP-1 and 2 were
uantified in the supernatants by enzyme-linked immunosorbent
ssay (TIMP-1 and TIMP-2 Biotrak enzyme-linked immunosor-
ent assay, Amersham Biosciences Corp). Because of the limiting
actor of tissue quantity in each control patient (aortic punch), not
ll control tissue underwent both MMP and TIMP analyses. MMP
nalysis was performed in all 17 control patients. Nine of these 17
atients also underwent TIMP analysis and proteolytic index cal-
ulation. In the remaining 8 patients, limited tissue quantity ex-
luded TIMP analysis. Both MMP and TIMP levels were stan-
ardized to total protein. Values are expressed as nanograms of
MP or TIMP per milligram of protein.
ene Expression Analysis
eal-time quantitative polymerase chain reaction analysis was
erformed to assess MMP and TIMP mRNA expression in ran-
omly selected tissue (8 atherosclerotic, 11 nonatherosclerotic, and
control). The tissue from both aneurysm groups that underwent
RNA analysis also underwent MMP activity and TIMP protein
nalysis. Because of limited tissue from control subjects, mRNA
nalysis was performed on separate tissue that did not undergo
oncomitant MMP and TIMP analysis. Total RNA from tissue
amples was extracted in TRIzol Reagent (Invitrogen Corp, Carls-
ad, Calif) by homogenization in a Polytron (Kinematica AG,
ucerne, Switzerland) device, followed by centrifugation and fur-her extraction with chloroform. The RNA in the aqueous layer
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A
CDas precipitated with isopropyl alcohol and washed with ethanol.
he sample was resuspended in water and further purified using the
Neasy Fibrous Tissue Mini Kit from Qiagen, Inc (Valencia, Calif),
ccording to the manufacturer’s instructions. An aliquot was mea-
ured for concentration and quality analysis using an Agilent 2100
ioanalyzer (Palo Alto, Calif) at the Vermont Cancer Center’s
NA Analysis Core Facility (Burlington, Vt). Only samples with
n appropriate yield of intact mRNA were used.
Real-time quantitative polymerase chain reaction was per-
ormed with the Applied Biosystems GeneAmp RNA PCR Core
it (Foster City, Calif). Briefly, a 25-L reaction mixture contain-
ng a 1-g purified sample of RNA with 5 mmol/L MgCl2 1X PCR
uffer II, 1 mmol/L each of deoxyguanosine triphosphate, deoxya-
enosine monophosphate, deoxythymidine triphosphate, and de-
xycytidine triphosphate, 1 U/mL RNase inhibitor, 2.5 U/L
uLV reverse transcriptase, and 2.5 mol oligo d(T) was reverse
ranscribed at 42°C for 15 minutes, followed by an additional
ncubation at 99°C for 5 minutes.
Complementary DNA samples were analyzed with Applied
iosystem’s Assays-on-Demand Gene Expression products.
he reaction mixture consisted of 1X Taqman Universal PCR
aster Mix (20X unlabeled polymerase chain reaction primers
nd TaqMan MGB [FAM dye labeled] probe) and 1X Assays-
n-Demand Gene Expression Assay Mix (specific mRNA
robes: Hs00234433_m1 [MMP-2], Hs00234579_m1 [MMP-
], Hs00171558_m1 [TIMP-1], Hs00234278_m1 [TIMP-2],
nd Hs00355752_m1 [hypoxanthine guanine phosphoribosyl
ransferase]). The reactions were performed with Applied Bio-
ystem’s Prism 7700 Sequence Detection System at 40 cycles
95°C for 15 seconds and 60°C for 60 seconds).
Relative MMP and TIMP mRNA expression was calculated by
he comparative CT method, using hypoxanthine guanine phospho-
ibosyl transferase as the endogenous control. Standard curves
ere run to validate the efficiencies of target and reference mRNA;
hey were approximately equal. Each target in the aneurysm
roups was then normalized to the control group to obtain relative
ABLE 1. Patient demographics
Control
N  17 (%)
ge (mean, y) 64.1 13.0
ize (mean, cm)
ex (male) 13 (76)
scending aorta involvement 17 (100)
icuspid valve 0 (0)
ypertension 12 (71)
yperlipidemia 13 (77)
obacco use 2 (12)
AD 17 (100)
-blocker 10 (59)
a2 blocker 2 (12)
CE inhibitor 7 (41)
AD, coronary artery disease; ACE, angiotensin-converting enzyme.uantification values. e
The Journal of Thoracictatistical Analysis
ata are given as mean values  standard deviation. Differences
n means between groups were tested using the unpaired Student
test and analysis of variance. Nonparametric analysis was per-
ormed with the Kruskal–Wallis Test when there was evidence of
nequal variance. Pearson chi-square analysis was used to com-
are clinical variables between groups. The relationship among
neurysm size, MMP activity, and TIMP levels was assessed with
imple linear regression analysis.
esults
atients
atient demographic and clinical variables are presented in
able 1. Those in the nonatherosclerotic group were
ounger than those in the other 2 groups (P  .02). The
verage age of controls who underwent both MMP and
IMP analyses was 64.7  4.8 years. The average age of
ontrols who underwent mRNA analysis alone was 69  3
ears (atherosclerotic: 68.3  4 years, nonatherosclerotic:
9  4 years, P  .10).
Atherosclerotic aneurysms were larger than nonathero-
clerotic aneurysms (P  .01). Nonatherosclerotic aneu-
ysms occurred more frequently in the proximal aorta and
ere often associated with a bicuspid aortic valve. There
ere differences between groups with regard to tobacco use,
yperlipidemia, and coronary artery disease.
MP Activity and TIMP Levels
he endogenous MMP-2 activity was greater in controls
han in either aneurysm group (P  .002). A positive
orrelation existed between aneurysm size and endogenous
MP-2 activity in the atherosclerotic group (R2  0.30)
P  .004, Figure 1). The total MMP-2 activity was greater
n controls than in either aneurysm group (P  .002). The
ndogenous MMP-9 activity was greater in controls than in
therosclerotic
n  24 (%)
Nonatherosclerotic
N  63 (%) P value
69.5 10.6 58.7 14.0 .02
6.1 0.9 5.6  0.8 .01
12 (50) 49 (78) .06
12 (50) 59 (94) .001
3 (13) 28 (45) .005
15 (65) 31 (49) .18
13 (57) 21 (33) .003
13 (57) 17 (27) .005
13 (57) 23 (37) .001
13 (57) 36 (57) .99
7 (30) 6 (10) .05
10 (44) 20 (32) .54Aither aneurysm group (P  .002). The total MMP-9 activ-
and Cardiovascular Surgery ● Volume 133, Number 1 157
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1
A
CDty was greater in the atherosclerotic group when compared
ith the nonatherosclerotic group and controls (P  .001).
IMP-1 levels were greater in controls than in either
neurysm group (P  .003). TIMP-2 levels were also
reater in controls than in either aneurysm group (P 
001) (Table 2).
Subgroup analysis of the regional differences in MMP
nd TIMP expression in the thoracic aorta was possible in
he atherosclerotic group. There were no meaningful differ-
nces in the regional expression of TIMP-1, TIMP-2, en-
ogenous MMP-2 and MMP-9, or total MMP-9. Athero-
clerotic ascending thoracic aneurysms expressed more total
MP-2 than atherosclerotic descending thoracic aneurysms
P  .03) (Table 3).
roteolytic Index
he proteolytic state of the aortic wall is expressed as the
atio of total MMP activity to TIMP levels. Controls had a
igure 1. Endogenous activity of MMP-2 in the atherosclerotic
horacic aortic wall relative to aortic size (R2  0.30, P  .004).
MP-2, Matrix metalloproteinase-2.
ABLE 2. Matrix metalloproteinase activity, tissue inhibito
Control A
ndogenous MMP-2 1.54 1.6
otal MMP-2 80 67
ndogenous MMP-9 0.74 1.3
otal MMP-9 1.7 1.9
IMP-1 376 192
IMP-2 143 74
otal MMP-2:TIMP-1 0.11 0.06
otal MMP-2:TIMP-2 0.32 0.27
otal MMP-9:TIMP-1 0.01 0.009
otal MMP-9:TIMP-2 0.03 0.02MP, Matrix metalloproteinase; TIMP, tissue inhibitor matrix metalloproteinase
58 The Journal of Thoracic and Cardiovascular Surgery ● Januower ratio of MMP-2 activity to TIMP-1 levels than
ither aneurysm group, but this could be due to chance
P  .25). Controls had a lower ratio of MMP-2 activity
o TIMP-2 levels than either aneurysm group (P  .001).
ontrols had lower ratios of MMP-9 activity to both
IMP-1 (P  .02) and TIMP-2 (P  .001) when compared
ith either aneurysm group (Table 2). There was no meaning-
ul difference in the proteolytic index between atherosclerotic
scending aneurysms and atherosclerotic descending aneu-
ysms (Table 3).
ene Expression
therosclerotic aneurysms expressed almost 3 times more
MP-2 mRNA and 5 times more MMP-9 mRNA than
ontrols. Nonatherosclerotic aneurysms showed no differ-
nce in expression of MMP-2 mRNA when compared with
ontrols, but expressed 4 times more MMP-9 mRNA. Non-
therosclerotic aneurysms expressed less TIMP mRNA than
therosclerotic aneurysms and controls (Table 4).
trix metalloproteinase level, and proteolytic index
sclerotic Nonatherosclerotic P value
 0.53 0.61  0.71 .002
 50 35  44 .002
 0.42 0.17 0.19 .002
 15.7 2.5  2.2 .001
 233 174  148 .003
 13 27  43 .001
 0.55 0.33 0.53 .25
 7.1 2.8  5.5 .001
 0.12 0.03 0.08 .02
 7.7 0.24 0.36 .001
ABLE 3. Regional expression of matrix metalloproteinase
ctivity, tissue inhibitor matrix metalloproteinase levels,
nd proteolytic index in atherosclerotic aneurysms
Ascending
(n  12)
Descending
(n  12) P value
ndogenous MMP-2 0.56 0.58 0.72 0.49 .47
otal MMP-2 71 59 26 20 .03
ndogenous MMP-9 0.22 0.42 0.29 0.45 .69
otal MMP-9 8.5 8.4 14.8 20.5 .36
IMP-1 274 224 173 240 .31
IMP-2 14.5 10.0 11.9 15.7 .64
otal MMP-2:TIMP-1 0.52 0.72 0.29 0.30 .36
otal MMP-2:TIMP-2 8.5 7.8 4.8 5.8 .24
otal MMP-9:TIMP-1 0.05 0.07 0.12 0.16 .14
otal MMP-9:TIMP-2 1.2 1.5 4.6 10.5 .33
MP, Matrix metalloproteinase; TIMP, tissue inhibitor matrix metal-
oproteinase.r ma
thero
0.64
49
0.25
11.7
234
14
0.39
7.0
0.08
3.1.
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A
CDiscussion
here is strong evidence that enhanced MMP activity and/or
educed TIMP levels contribute to abdominal aortic aneu-
ysm growth and rupture.1-3,5 The supposition that these
ame pathologic conditions exist in thoracic aortic aneu-
ysms is unproven, given the differences in the histologic
attern of disease between these two types of aneurysms.
ost abdominal aortic aneurysms are atherosclerotic in
ause and are associated with an inflammatory cell infiltrate.
he inflammatory environment associated with the ather-
ma results in the increased expression of MMPs.2,3
MP-9 activity predominates because of its association
ith the tissue macrophage.7
Unlike abdominal aortic aneurysms, thoracic aortic an-
urysms occur as 2 distinct histopathologic subtypes: ath-
rosclerotic and nonatherosclerotic. Attempts at defining the
ole of the metalloproteinases and their inhibitors in the
ormation of human thoracic aneurysms have been ham-
ered by the analysis of these two subtypes of aneurysms
ogether, the inclusion of acute aortic dissections with an-
urysms in data analysis, the use of small study groups, the
se of semiquantitative methodology for measuring MMP
nd TIMP expression, and the use of non–aged matched and
on–risk factor–matched controls.6,8-11 Animal models
ave aided in the understanding of the relationship of
MPs and TIMPs to the development of thoracic aneu-
ysms, but these models are inflammatory based12,13 and
herefore may not reflect the pathogenesis of the nonathero-
clerotic subgroup.
The inclusion of a well-matched control group is impor-
ant when interpreting the role of the MMPs and TIMPs in
xtracellular matrix turnover. Aging is known to increase
ABLE 4. Relative quantitation of aneurysm mRNA to con-
rol aorta
roup
Target
mRNA CT
Target relative to
control (range)
ON MMP-2 0.0 1.4 1.0 (0.4-2.6)
TH 1.5  3.6 2.7 (0.2-33.1)
OATH 0.2  2.3 1.1 (0.2-5.5)
ON MMP-9 0.0 1.5 1.0 (0.4-2.8)
TH 2.3  3.3 5.1 (0.5-51.3)
OATH 2.0 1.6 4.1 (0.3-12.5)
ON TIMP-1 0.0 1.5 1.0 (0.4-3.0)
TH 1.0  2.7 2.0 (0.3-13.5)
OATH 0.4 2.5 0.8 (0.1-4.3)
ON TIMP-2 0.0 1.5 1.0 (0.3-2.9)
TH 1.1  1.2 2.1 (0.9-4.8)
OATH 0.7 2.4 0.6 (0.1-3.4)
ON, Control; ATH, atherosclerotic; NOATH, nonatherosclerotic; MMP,
atrix metalloproteinase; TIMP, tissue inhibitor metalloproteinase; CT,
target mRNA  HPRT mRNA)  control group calibrator.he activity of MMP-2 in the rat,14 nonhuman primate,15 and m
The Journal of Thoracicuman nonaneurysmal aorta,16 and is associated with the
ncreased expression of both TIMP-117 and TIMP-215
ithin the nonaneurysmal aortic wall. Hypertension is as-
ociated with the increased expression of both MMP-2 and
MP-9 in the aortic wall.17,18 Thus, the use of an older
ontrol group with similar vascular risk factors as the ex-
erimental group is important to control for such variables
elated to MMP and TIMP expression.
This study used an aged control group with similar
ascular risk factors as the experimental groups and is
nique in its finding that both the endogenous and total
MP-2 activity were higher in the control group when
ompared with the aneurysm groups. Prior studies using
mall select groups of patients with nonatherosclerotic tho-
acic aneurysms, such as patients with bicuspid aortic
alves,9,19 found higher MMP-2 expression referable to
ontrols. Most of these studies, however, used tissue from
ounger patients (such as organ donors) as controls, which
ould confound the interpretation of MMP-2 expression
elative to the experimental group.
Subgroup analysis revealed that regional differences in
he expression of MMP-2 may partially account for the
ower total MMP-2 activity in the atherosclerotic group
hen compared with controls. Ascending atherosclerotic
neurysms had higher total MMP-2 activity than descending
therosclerotic aneurysms. Regional differences in MMP
xpression in the aorta have been documented in both
nimal20 and human studies.11 The location of tissue sam-
ling within the descending aneurysms may have also in-
uenced the results, because there is evidence that MMP-2
ctivity is lower in the anterior wall of descending thoracic
neurysms relative to the posterior wall.21
Another notable finding in this study was that both
IMP-1 and TIMP-2 protein expression were greater in the
ontrol group than in either aneurysm group. The higher
ontrol TIMP levels resulted in a lower proteolytic index
espite the elevated MMP-2 activity. The lower TIMP
rotein levels in the nonatheroslerotic group referable to
ontrols were associated with reduced TIMP mRNA ex-
ression. The importance of inhibitor expression in the
athogenesis of thoracic aneurysms has been demon-
trated in TIMP-1-deficient mouse models of inflamma-
ion-induced thoracic aneurysms.12,13
The differences in MMP and TIMP expression between
he controls and the nonatherosclerotic group should be
nterpreted relative to known age-related aortic wall remod-
ling. Normal aging is associated with an increase in aortic
iameter and a compensatory thickening of the aortic wall
s a means to normalize circumferential wall stress.22,23
ortic wall thickening with aging is associated with non-
nflammatory cell proliferation in the intima, medial smooth
uscle cell hypertrophy, and a net increase in extracellular
atrix production.15 These events are linked to increases in
and Cardiovascular Surgery ● Volume 133, Number 1 159
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A
CDmooth muscle cell expression of both MMP-215,24 and
IMP-2.15 TIMP-2 can both induce and repress the activity
f MMP-215 and has been associated with induction of cell
roliferation.15,25
Nonatherosclerotic thoracic aneurysms, however, are as-
ociated with a progressive thinning of the aortic wall over
ime. These aneurysms were found to express much lower
MP-2 activity, TIMP protein, and TIMP mRNA when
ompared with the aged controls. It is plausible that both
ortic wall thinning and a reduction in MMP/TIMP expres-
ion in nonatherosclerotic thoracic aneurysms are related
o the dysfunction or loss of the smooth muscle cell, the
ngine that drives the normal age-related eutrophic aortic
all remodeling. Smooth muscle cell apoptosis has been
ocumented in some types of nonatherosclerotic thoracic
neurysms.26,27
Previous animal and human studies have explored the
elationship of MMP-9 expression and the pathogenesis of
onatherosclerotic thoracic aneurysms. Intense MMP-9 im-
unostaining was seen in the aneurysmal aortic walls of
ice in a genetic knockout model of Marfan syndrome.28
his expression, however, was associated with an inflam-
atory cell infiltrate, a histologic finding that is not char-
cteristically seen in aortic aneurysms of patients with
arfan syndrome. MMP-9 immunoreactivity was seen in
neurysm tissue from a small study of humans with Marfan
yndrome,10 but only in regions of inflammatory cell infil-
ration that may have occurred secondary to the trauma of
cute aortic dissection in almost half of the patients. The
onfounding presence of an inflammatory infiltrate, there-
ore, may affect the conclusions in these studies. We did
nd increased MMP-9 mRNA expression in the nonathero-
clerotic group relative to controls, but this was not associ-
ted with an increase in MMP-9 protein activity.
It was hypothesized that atherosclerotic thoracic aneu-
ysms would have a similar MMP/TIMP phenotype with
bdominal aneurysms given the presence of an inflamma-
ory infiltrate. This was confirmed in our study by the
ndings that both the total MMP-9 activity and MMP-9
RNA expression were higher when compared with con-
rols. Because there was no meaningful difference in total
MP-9 activity between the controls and the nonathero-
clerotic group, it is suggested that the enhanced MMP-9
ctivity associated with the inflammatory infiltrate is unique
o atherosclerotic aneurysms. Although atherosclerotic aneu-
ysm tissue expressed twice as much TIMP-1 and TIMP-2
RNA relative to controls, this was not associated with higher
IMP protein levels. Similar findings have been noted in
therosclerotic abdominal aneurysms.29 The lower protein
xpression relative to the higher transcriptional expression
ould indicate an alteration in the posttranscriptional pro-
essing of mRNA, differences in mRNA stabilization, or
osttranslational control between groups. A similar relation- M
60 The Journal of Thoracic and Cardiovascular Surgery ● Januhip was seen in the expression of MMP-2 mRNA and
MP-2 activity in the atherosclerotic group.
This study supports the concept that MMP/TIMP ho-
eostasis is altered in thoracic aortic aneurysms. The spe-
ific alteration, however, is peculiar to the subtype of an-
urysm. The atherosclerotic thoracic aneurysm behaves
imilarly to the atherosclerotic abdominal aneurysm in re-
ard to MMP/TIMP metabolism. These aneurysms have
ocally thickened walls with atheroma containing an inflam-
atory cell infiltrate that overexpresses MMP-9, which may
ead to focal wall weakening and expansion. In contrast, the
onatherosclerotic aneurysm is characterized by nonfocal
hinning of the aortic wall. The lesion is associated with a
aucity of cells, mainly from the loss of the smooth muscle
ell. There is no inflammatory cell infiltrate. With loss or
ysfunction of the smooth muscle cell and, with it, the
nability to synthesize and secrete MMP-2 and TIMP, the
ortic wall may lose the ability to compensate for age-
elated hemodynamic stress with reactive thickening. This
ould predispose the aortic wall to further weakening and
ubsequent dilatation.
There are limitations associated with this work. A cause
nd effect relationship between MMP and TIMP expression
nd aneurysm formation cannot be made, because aneurysm
pecimens were limited to patients with advanced disease.
ecause we did not perform smooth muscle cell and mac-
ophage quantification, the supposition that the lower ex-
ression of MMP-2 and TIMP seen in the nonatheroscle-
otic group, or the higher MMP-9 expression seen in the
therosclerotic group, is related to these cells is purely
peculative and based on past literature. The control
roup was limited to tissue obtained from the ascending
orta, and as noted above, regional differences in MMP/
IMP expression may occur within the aorta. Our control
roup, therefore, may not completely represent the entire
ross-section of metalloproteinase expression within the
orta.
onclusions
horacic aneurysms were found to have divergent MMP/
IMP phenotypes based on their histologic classification.
therosclerotic thoracic aneurysms have increased tran-
criptional expression and activity of MMP-9 and decreased
xpression of TIMP protein, and are similar to abdominal
neurysms in this regard. Nonatherosclerotic thoracic aneu-
ysms have reduced MMP-2 activity and TIMP protein and
ene expression when compared with nonaneurysmal aorta,
hich may reflect a loss or dysfunction of the smooth
uscle cell and the inability to compensate for age-related
emodynamic stress.
The authors thank Steven R. Shackford, MD, and Sarah Howe,
A, for their help in preparing this article.
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